Experimental immune cell combo targets Drug-Resistant lung cancer
NCT ID NCT07330050
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether a new immune cell treatment called WAST cells, combined with the chemotherapy drug docetaxel, can shrink tumors or slow disease in people with advanced non-small cell lung cancer that has stopped responding to PD-1 inhibitors. The study plans to enroll 31 participants and will measure how many patients respond to the treatment, as well as how long they live without the cancer getting worse. The goal is to find a new option for patients who have run out of effective therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
WAST cells (a type of immune cell) and docetaxel (chemotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer that has stopped responding to standard immunotherapy.
What could go wrong
This is a small, early-phase trial with only 31 participants, so results may not apply to everyone. The treatment involves chemotherapy, which has known side effects like fatigue and infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••